匹伐他汀联合利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝的疗效

Efficacy of pitavastatin combined with liraglutide in the treatment of type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

目的探讨匹伐他汀联合利拉鲁肽治疗2型糖尿病(T2DM)合并非酒精性脂肪肝(NAFLD)的疗效。方法选取2019年8月-2021年1月在天津医科大学朱宪彝纪念医院收治的108例T2DM合并NAFLD患者为研究对象,采用随机数字分类法分为对照组(n=54)与试验组(n=54)。对照组采用利拉鲁肽治疗,试验组采用匹伐他汀联合利拉鲁肽进行治疗。比较2组患者治疗前后的血糖水平、肝功能指标、血脂情况及用药安全性,从而评价联合治疗的临床效果。结果治疗后,试验组与对照组患者的空腹血糖分别是(7.12±0.22)和(7.86±0.34)mmol·L^(-1);餐后2h血糖分别是(8.85±0.28)和(9.17±0.35)mmol·L^(-1);糖化血红蛋白分别是(6.66±0.90)%和(7.78±1.12)%;总胆固醇分别是(5.79±0.64)和(6.39±0.82)mmol·L^(-1);甘油三酯分别是(1.52±0.42)和(1.85±0.53)mmol·L^(-1);低密度脂蛋白胆固醇分别是(3.17±0.56)和(3.81±0.51)mmol·L^(-1);谷丙转氨酶分别是(52.09±9.01)和(56.42±9.78)U·L^(-1);谷草转氨酶分别是(70.89±7.09)和(75.04±6.01)U·L^(-1);谷氨酰转移酶分别是(82.16±5.74)和(85.87±6.65)U·L^(-1),上述指标,对照组与试验组对比,差异均有统计学意义(均P<0.05);试验组与对照组的总药物不良反应发生率分别为11.11%和14.81%,2组比较,差异无统计学意义(P>0.05)。结论匹伐他汀联合利拉鲁肽治疗2型糖尿病合并非酒精性脂肪肝的临床疗效较好,对血糖、血脂及肝功能的改善情况均优于利拉鲁肽单一治疗,且具有较高的安全性。

Objective To investigate the of pitavastatin combined with liraglutide in the treatment of type 2 diabetes mellitus(T2DM)complicated with non-alcoholic fatty liver disease(NAFLD).Methods A total of 108 patients with T2DM and NAFLD who were admitted to Tianjin Medical University Chu Hsien^(-1) Memorial Hospital from August 2019 to January 2021 were selected as the research objects,and divided into the control group(n=54)and the treatment group(n=54)by random number classification.The control group was treated with liraglutide monotherapy,and the treatment group was treated with pitavastatin combined with liraglutide.To compare the blood glucose level,liver function index,lipid profile and medication safety of the two groups before and after treatment,so as to evaluate the clinical effect of the combined treatment.Results After treatment,the fasting blood glucose of the treatment group and the control group were(7.12±0.22)and(7.86±0.34)mmol·L^(-1);2 h postprandial blood glucose were(8.85±0.28)and(9.17±0.35)mmol·L^(-1);glycosylated hemoglobin was(6.66±0.90)%and(7.78±1.12)%;the total cholesterol were(5.79±0.64)and(6.39±0.82)mmol·L^(-1);triglycerides were(1.52±0.42)and(1.85±0.53)mmol·L^(-1);low density lipoprotein cholesterol were(3.17±0.56)and(3.81±0.51)mmol·L^(-1);the alanine aminotransferase was(52.09±9.01)and(56.42±9.78)U·L^(-1);aspartate aminotransferase were(70.89±7.09)and(75.04±6.01)U·L^(-1);the glutamine transferases were(82.16±5.74)and(85.87±6.65)U·L^(-1).The above indexes were significantly different between the control group and the treatment group(all P<0.05).The incidence of total adverse drug reactions in the treatment and control groups was 11.11%and 14.81%,with no statistically significant differences between groups(P>0.05).Conclusion The clinical efficacy of pitavastatin combined with liraglutide in the treatment of T2DM complicated with NAFLD is better;the improvement of blood sugar,blood lipid and liver function were better than the single treatment of liraglutide,and it has high safety.